BiotechTube
SarcoMed USA

SarcoMed USA

New York, United States· Est.
sarcomedusa.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SarcoMed USA is a private, preclinical-stage biotech company targeting significant unmet needs in pulmonary inflammation, primarily pulmonary sarcoidosis. Its core strategy involves repurposing or licensing inhaled DNase 1 enzyme therapy (SM001) to break down pro-inflammatory extracellular DNA complexes implicated in granuloma formation. The company has completed a Pre-IND meeting with the FDA, secured orphan designation, and is exploring additional indications like ARDS and IPF, while also holding an option on an immuno-oncology asset. It appears to be pre-revenue and is advancing toward clinical trials.

Pulmonary & RespiratoryImmunologyOncology

Technology Platform

Application of inhaled DNase 1 enzyme therapy to degrade extracellular DNA implicated in driving granulomatous inflammation and fibrosis in pulmonary diseases.

Opportunities

The primary opportunity is addressing the significant unmet need in Pulmonary Sarcoidosis, a billion-dollar orphan market with no approved disease-specific therapies.
Success with SM001 could establish a new treatment paradigm and provide a platform for expansion into larger inflammatory and fibrotic lung disease markets like ARDS and IPF.

Risk Factors

Key risks include the unproven clinical efficacy of the DNase hypothesis in sarcoidosis, reliance on future financing to advance trials, and execution risks associated with a small private biotech.
Competition in broader respiratory indications and the challenge of navigating regulatory approval for a first-in-class therapy are additional concerns.

Competitive Landscape

In Pulmonary Sarcoidosis, the competitive landscape is sparse with no approved targeted biologics, positioning SM001 as a potential first-in-class agent. However, in its secondary target indications (ARDS, IPF, CF), it would face intense competition from large pharma and biotech companies with approved therapies and deep pipelines.

More companies in Biologics / Biosimilars →More companies in United States →